Novo Nordisk Takes Legal Fight to Lilly as GLP-1 Ad War Reaches Boiling Point
Published on 07/23/2026 at 14:21 | Redaktion boerse-global.de
The simmering rivalry between Novo Nordisk and Eli Lilly has spilled into a federal courtroom, with the Danish drugmaker filing a lawsuit on July 21, 2026, in New Jersey that accuses its US competitor of running deceptive advertisements for the weight-loss drugs Mounjaro and Zepbound. The complaint, lodged under the Lanham Act, marks the most aggressive escalation yet in a battle that has already reshaped the multibillion-dollar GLP-1 market.
At the heart of the dispute are the dosages each company highlights in its marketing. Novo contends that Lilly’s TV and social media campaigns — which have generated more than 700 million impressions since late April — compare the highest approved doses of Zepbound and Mounjaro with outdated, lower doses of Wegovy and Ozempic. Lilly has built its messaging around the SURMOUNT-5 study, published in 2024, which showed a weight loss of 50 pounds with Zepbound versus 33 pounds with Wegovy. But Novo counters that when both drugs are compared at their maximum approved doses, the difference shrinks to just 48 pounds versus 47 pounds — a gap it calls clinically insignificant.
Novo points to a key development that it says Lilly has ignored: the US Food and Drug Administration approved a higher 7.2-milligram dose of Wegovy in March 2026, which produces weight loss of roughly 19 percent — comparable to Zepbound’s results. The company had already demanded in April that Lilly pull the ads, but the US rival only added a disclaimer and kept the campaign running. Novo is now seeking a preliminary injunction, corrective advertising, and unspecified damages. Lilly has defended the campaign as scientifically sound, citing SURMOUNT-5 as the only head-to-head data comparing the two drug classes.
The legal clash comes at a delicate moment for Novo, which has seen its market position erode. In the first quarter of 2026, Lilly’s Mounjaro generated $8.7 billion in sales, while Wegovy brought in roughly $3 billion. Lilly’s total revenue surged 55.5 percent to $19.8 billion, and the company now commands 60.1 percent of the US GLP-1 market, compared with Novo’s 39.4 percent. For the full year, Lilly is targeting revenue of $82 billion to $85 billion.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Novo CEO Mike Doustdar has been working to restore investor confidence after a series of setbacks. At the ADA conference in New Orleans in early June, he highlighted that the oral Wegovy pill has surpassed 3 million prescriptions, with 225,000 new weekly orders. He argued that Wegovy offers superior weight loss, better heart protection, and fewer restrictions than competing drugs. But days later, he acknowledged to the Danish newspaper Børsen that investors remain skeptical following steep share price declines — most notably the 16 percent single-day plunge in February 2026 triggered by disappointing results from the Cagrisema study.
The stock has yet to recover. Novo shares were trading at €42.05 in Frankfurt, down 6.63 percent over the past seven trading sessions and 31 percent below the year’s high set last summer. At the close on Wednesday, the stock stood at €42.09, reflecting a daily loss of 3.22 percent. Over the past twelve months, the shares have fallen 29.17 percent. The immediate market reaction to the lawsuit was muted — Lilly shares edged higher while Novo’s dipped slightly, according to Axios.
To counter the pressure, Novo has accelerated a 15 billion Danish krone share buyback program. The company also plans to cut Wegovy’s list price in half starting in 2027, a move that could squeeze margins but may help defend market share as Lilly continues to gain ground.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Broader industry dynamics are also shifting. The global weight-loss drug market, valued at $4.21 billion in 2025, is projected to reach $23.59 billion by 2030, while some estimates peg the GLP-1 segment alone at $100 billion by the end of the decade. In the UK, the National Health Service is now offering Wegovy to 1.2 million patients with cardiovascular disease, following studies showing a 20 percent reduction in the risk of major heart problems. In the US, a Medicare bridge program launched on July 1, 2026, gives older patients with obesity access to GLP-1 drugs for $50 per month — potentially widening Wegovy’s customer base while also intensifying direct comparisons with Lilly’s products.
Adding another layer of uncertainty, Washington has announced a phased tariff plan on imported generics, starting at zero percent through August 2026, then rising to 100 percent in 2028 and 200 percent in 2029. While that could eventually benefit established players like Novo by making copycat drugs more expensive, it also signals that pricing pressure in the US market is likely to persist regardless of how the advertising lawsuit is resolved. Both Novo and Lilly have already signed Most Favored Nation agreements with the US government, underscoring the long-term cost challenges facing the industry.
Ad
Novo Nordisk Stock: New Analysis - 23 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
